Bruce Aronow PhD


Bruce Aronow PhD
ProfessorCollege of Medicine--UCbruce.aronow@cchmc.org
S.10.248 240 Albert Sabin Way Cincinnati OH 45229
Phone:513-636-4865Fax: 513-636-2056
  • Molecular Biology and Cancer Genetics

General Research Interest

Systems biology of oncogenesis and malignancy.  Prediction of drug targets and optimal therapeutics based on integrative knowledge analysis of individual cancers oncogenome.

Research Description

Dr. Aronow's research efforts are directed to the goal of bringing complete knowledge of gene functions and gene activity to the analysis disease mechanisms.  To do this he works with investigators in many different areas of research to use technologies that measure gene activity and gene variation and mutation across the whole genome. His group works on the analysis of data and the development of databases that help researchers to predict active pathways of cancer based on gene expression analyses using gene expression and gene variation -sensitive microarrays and next-generation sequencing technologies.  He is now working on the development of new database system that uses extensive knowledge and data that profiles drug sensitivities of different cancers to help predict the powerful therapeutic agents against different cancers.

Transinstitutional Work

Dr. Aronow is collaborating with several investigators from the James and the The Research Institute at Nationwide Children's Hospital in order to understand the molecular basis of colon cancer malignancy and the regulation of gene expression and differentiation of stem cells.

Current Publications

  • Grimes HLTherapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.J Clin Invest 124 222-36 1/2/2014
  • Akdemir KC, Jain AK, Allton K, Aronow B, Xu X, Cooney AJ, Li W, Barton MCGenome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells.Nucleic Acids Res in press 9/27/2013
  • Aronow BJ, Saba I, Zeng H, Kosan C, Messer MS, Olsson HA, Fraszczak J, Hildeman DA, , Möröy T, Grimes HLGrowth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors.PLoS Genet 9(9) e1003713 9/1/2013
  • Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow B, Cripe TP, Ratner NMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123(1) 340-7 1/2/2013
  • Subramani A, Alsidawi S, Jagannathan S, Sumita K, Sasaki AT, Aronow B, Warnick RE, Lawler S, Driscoll JJThe brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis.Sci Rep 3 2392 1/1/2013
  • Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow B, Perentesis J, Serra E, Cripe T, Miller SC, Ratner NRas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18(18) 5020-30 9/15/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu